Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 55Stomach Neoplasms 27Pancreatic Neoplasms 18Rectal Neoplasms 16Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Neoplasm Metastasis 10Esophageal Squamous Cell Carcinoma 8Esophageal Neoplasms 8Colonic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Adenocarcinoma 8Head and Neck Neoplasms 7Gastrointestinal Neoplasms 6Biliary Tract Neoplasms 6Adenocarcinoma Of Esophagus 6Ovarian Neoplasms 5Peritoneal Neoplasms 4Advanced Solid Tumors 4Urinary Bladder Neoplasms 3Nasopharyngeal Carcinoma 3Lung Neoplasms 3Endometrial Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma 3Breast Neoplasms 3Appendiceal Neoplasms 3Locally Recurrent Rectal Cancer 2

Interventions

beta-D-glucosylisophosphoramide mustard 1Telemedicine 1Taxes 1Practice Guidelines as Topic 1Gemcitabine 1Fluorouracil 1Counseling 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Pancreatic Adenocarcinoma × Fluorouracil × Clear all
NCT01954992 2024-12-31

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Eleison Pharmaceuticals LLC.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡